Photo taken from: Al-Ola A Abdallah/X
Aug 27, 2024, 23:06
Al-Ola A Abdallah: What’s the best approach after M protein reappearance in high-risk Smoldering Myeloma?
Al-Ola A Abdallah, Plasma Cell Disorder Program Director, Division of HMCT/University of Kansas Medical Center, made the following post on X:
“Patient with high-risk Smoldering Myeloma t(4;14) was enrolled in a trial, received aggressive treatment for 2 years, and achieved MRD negativity. After 3 years, M protein reappeared at the same level as when enrolled in the trial, with no evidence of end organ damage.
- Start Dara-RVd/ASCT
- Survillance monthly
- Surveillance Q3 Months
- Start lenalidomide.”
Source: Al-Ola A Abdallah/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 12, 2024, 23:10
Nov 12, 2024, 23:07
Nov 12, 2024, 22:58
Nov 12, 2024, 22:56
Nov 12, 2024, 22:50
Nov 12, 2024, 22:46
Nov 12, 2024, 22:43
Nov 12, 2024, 19:34